862310-92-7

Upstream product

• 1073340-39-2 3-[4-(1,4-dioxaspiro[4.5]dec-8-yloxy)phenyl]-2-methyl-4(3H)-quinazolinone 
• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 1789-09-9 1-(2-methyl-4-oxo-4H-quinazolin-3-yl)-4-hydroxybenzene 

Downstream Products

• 862310-90-5 trans-2-methyl-3-(4-([4-(1-pyrrolidinyl)cyclohexyl]oxy)phenyl)-4(3H)-quinazolinone 
• 862310-88-1 cis-2-methyl-3-(4-([4-(1-pyrrolidinyl)cyclohexyl]oxy)phenyl)-4(3H)-quinazolinone 

Relevant academic research and scientific papers

Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists

A series of structurally constrained derivatives of the potent H 3 inverse agonist 1 was designed, synthesized, and evaluated as histamine H3 receptor inverse agonists. As a result, the N-cyclobutylpiperidin-4-yloxy group as in 2f wa

Fused ring 4-oxopyrimidine derivative

The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X1 is a nitrogen atom, sulfur atom or oxygen atom, R1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R2 and R3 are amino groups or alkylamino groups, and X2 is represented by formula (II): (where R4 and R5 are lower alkyl groups, and n is an integer from 2 to 4).]